Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 16

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 asset6 6 Stock-based compensation expense435 1,155 Changes in operating assets and liabilities, net:Accrued interest on marketable debt securities- (79)Prepaid expenses, other current assets, and other assets51 602 Accounts payable, accrued expenses and other liabilities866 (1,447)Net cash used in operating activities(1,989)(4,366)Cash flows from investing activities:Redemption of marketable debt securities- 3,260 Net cash provided by investing activities- 3,260 Cash flows from financing activities:Proceeds from ATM offering345 - Issuance costs related to ATM offering(17)- Proceeds from exercise of warrants and options- 8 Net cash provided by financing activities328 8 Net decrease in cash and cash equivalents(1,661)(1,098)Cash and cash equivalents at beginning of period2,590 8,556 Cash and cash equivalents at end of period$929 $7,458 

The accompanying notes are an integral part of these condensed financial statements.

4

INTENSITY THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

Note 1.    Description of Business

Intensity Therapeutics, Inc. (the “Company”) is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRxSM technology platform has identified a lead drug, INT230-6.  The Company is based in Connecticut and was incorporated in Delaware in December 2012.  

The Company has completed two clinical studies and enrolled over 200 patients using INT230-6 in a Phase 1/2 dose escalation study in metastatic cancers including sarcomas, and a Phase 2 randomized control clinical trial in locally advanced breast cancer in women without undergoing chemotherapy prior to their surgery. In 2024, the Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study"), testing INT230-6 as second or third-line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Also in 2024, the Company initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, SAKK (the "INVINCIBLE-4 Study") evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple